摘要 |
This invention provides the use of a silicone-based transdermal therapeutic system having an area of 10 to 40 cm<2> and containing 0.1 to 3.15 mg / cm<2> of Rotigotine as active ingredient, for the preparation of an anti-Parkinson medicament which effects an improvement, compared to a placebo treatment, of the condition of human Parkinson patients, measured according to the Unified Parkinson's Disease Rating Scale (UPDRS) parts II and III, of 2 units or more following administration for a time period of at least 7 weeks. |